# BENEFIT Study (Betaferon® / Betaseron® in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study

> **NCT00185211** · PHASE3 · COMPLETED · sponsor: **Bayer** · enrollment: 468 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** Interferon beta-1b (Betaseron, BAY86-5046)
- **DRUG:** Interferon beta-1b (Betaseron, BAY86-5046)

## Key facts

- **NCT ID:** NCT00185211
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-08
- **Primary completion:** 2008-05
- **Final completion:** 2008-05
- **Target enrollment:** 468 (ACTUAL)
- **Last updated:** 2013-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00185211

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00185211, "BENEFIT Study (Betaferon® / Betaseron® in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00185211. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*